Lessons From Biotech Entrepreneurs: Pitching Your First-In-Class Innovation
Scientific Leaders From Nurix, Arrakis And Strand Therapeutics On Hitting ‘Undruggable’ Targets
Executive Summary
The role of biopharma start-ups in bringing innovative therapies to the market has grown enormously. These waves of new specialist companies often have the most innovative approaches to targeting a disease, and big pharma has become increasingly reliant on their fresh ideas to power pipelines.
You may also be interested in...
Protein Degradation Leader Nurix Prepares First Clinical Trial
After raising nearly $330m this year, via a financing and IPO, the company is gearing up for a first-in-human trial using its platform technology.
Arrakis Inks First Partnership In RNA-Targeted Collaboration With Roche
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.